JP2020531443A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531443A5 JP2020531443A5 JP2020508498A JP2020508498A JP2020531443A5 JP 2020531443 A5 JP2020531443 A5 JP 2020531443A5 JP 2020508498 A JP2020508498 A JP 2020508498A JP 2020508498 A JP2020508498 A JP 2020508498A JP 2020531443 A5 JP2020531443 A5 JP 2020531443A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- optionally substituted
- pharmaceutically acceptable
- acceptable salt
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 119
- 150000003839 salts Chemical class 0.000 claims description 76
- 229910052739 hydrogen Inorganic materials 0.000 claims description 51
- 239000001257 hydrogen Substances 0.000 claims description 51
- 150000002431 hydrogen Chemical class 0.000 claims description 45
- -1 substituted Chemical class 0.000 claims description 37
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 12
- 208000007502 anemia Diseases 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
- 208000007475 hemolytic anemia Diseases 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 150000001721 carbon Chemical group 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 6
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 6
- 208000035185 Hemolytic Congenital Anemia Diseases 0.000 claims description 4
- 206010060893 Hereditary haemolytic anaemia Diseases 0.000 claims description 4
- 208000002903 Thalassemia Diseases 0.000 claims description 4
- 201000001516 congenital hemolytic anemia Diseases 0.000 claims description 4
- 208000024987 familial hemolytic anemia Diseases 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- 208000007056 sickle cell anemia Diseases 0.000 claims description 4
- 125000003107 substituted aryl group Chemical group 0.000 claims description 4
- 108700014121 Pyruvate Kinase Deficiency of Red Cells Proteins 0.000 claims description 3
- 206010014490 Elliptocytosis hereditary Diseases 0.000 claims description 2
- 208000018565 Hemochromatosis Diseases 0.000 claims description 2
- 208000001825 Hereditary elliptocytosis Diseases 0.000 claims description 2
- 208000004622 abetalipoproteinemia Diseases 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 208000005980 beta thalassemia Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 208000009601 hereditary spherocytosis Diseases 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 230000000422 nocturnal effect Effects 0.000 claims description 2
- 230000001314 paroxysmal effect Effects 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 7
- 208000030760 Anaemia of chronic disease Diseases 0.000 claims 1
- 208000022400 anemia due to chronic disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 0 C*C(C1=O)=CC=NCC1(C)[Rn](C)C(C)N Chemical compound C*C(C1=O)=CC=NCC1(C)[Rn](C)C(C)N 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 108020005115 Pyruvate Kinase Proteins 0.000 description 2
- 102000013009 Pyruvate Kinase Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 description 1
- RTINBBNUUQZXQW-AATRIKPKSA-N CC(N)[Rn](C)/C(/C)=C/N=C Chemical compound CC(N)[Rn](C)/C(/C)=C/N=C RTINBBNUUQZXQW-AATRIKPKSA-N 0.000 description 1
- JCGZIBQMKYESAK-UHFFFAOYSA-N CCCN(C=CC(C)(C=N1)[Rn](C)C)C1=O Chemical compound CCCN(C=CC(C)(C=N1)[Rn](C)C)C1=O JCGZIBQMKYESAK-UHFFFAOYSA-N 0.000 description 1
- WHXNOIJKJFYUSM-UHFFFAOYSA-N C[n](c1c2C=NN(Cc(nc(cc3)N)c3F)C1=O)c1c2[s]c(Cc2n[nH]cc2)n1 Chemical compound C[n](c1c2C=NN(Cc(nc(cc3)N)c3F)C1=O)c1c2[s]c(Cc2n[nH]cc2)n1 WHXNOIJKJFYUSM-UHFFFAOYSA-N 0.000 description 1
- FXZBMEYGWLGHNX-UHFFFAOYSA-N C[n](c1c2C=NN(Cc3c[s]nc3)C1=O)c1c2[s]c(Cc2n[nH]cc2)n1 Chemical compound C[n](c1c2C=NN(Cc3c[s]nc3)C1=O)c1c2[s]c(Cc2n[nH]cc2)n1 FXZBMEYGWLGHNX-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023005925A JP7530453B2 (ja) | 2017-08-15 | 2023-01-18 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
| JP2024121066A JP2024147805A (ja) | 2017-08-15 | 2024-07-26 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2017/097496 | 2017-08-15 | ||
| CN2017097496 | 2017-08-15 | ||
| US201862673533P | 2018-05-18 | 2018-05-18 | |
| US201862673526P | 2018-05-18 | 2018-05-18 | |
| US62/673,526 | 2018-05-18 | ||
| US62/673,533 | 2018-05-18 | ||
| PCT/US2018/000128 WO2019035864A1 (en) | 2017-08-15 | 2018-08-15 | PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023005925A Division JP7530453B2 (ja) | 2017-08-15 | 2023-01-18 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531443A JP2020531443A (ja) | 2020-11-05 |
| JP2020531443A5 true JP2020531443A5 (https=) | 2021-09-30 |
| JP7275107B2 JP7275107B2 (ja) | 2023-05-17 |
Family
ID=63524352
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020508455A Active JP7301040B2 (ja) | 2017-08-15 | 2018-08-15 | ピルビン酸キナーゼ調節因子およびその使用 |
| JP2020508498A Active JP7275107B2 (ja) | 2017-08-15 | 2018-08-15 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
| JP2022199462A Pending JP2023027276A (ja) | 2017-08-15 | 2022-12-14 | ピルビン酸キナーゼ調節因子およびその使用 |
| JP2023005925A Active JP7530453B2 (ja) | 2017-08-15 | 2023-01-18 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
| JP2024121066A Pending JP2024147805A (ja) | 2017-08-15 | 2024-07-26 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020508455A Active JP7301040B2 (ja) | 2017-08-15 | 2018-08-15 | ピルビン酸キナーゼ調節因子およびその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022199462A Pending JP2023027276A (ja) | 2017-08-15 | 2022-12-14 | ピルビン酸キナーゼ調節因子およびその使用 |
| JP2023005925A Active JP7530453B2 (ja) | 2017-08-15 | 2023-01-18 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
| JP2024121066A Pending JP2024147805A (ja) | 2017-08-15 | 2024-07-26 | 血液障害の治療に使用するためのピルビン酸キナーゼ活性化因子 |
Country Status (34)
| Country | Link |
|---|---|
| US (8) | US11464775B2 (https=) |
| EP (4) | EP3668881B1 (https=) |
| JP (5) | JP7301040B2 (https=) |
| KR (3) | KR102642408B1 (https=) |
| CN (3) | CN111032045B (https=) |
| AU (4) | AU2018316588B2 (https=) |
| BR (1) | BR112020003254A2 (https=) |
| CA (1) | CA3072455A1 (https=) |
| CL (1) | CL2020000375A1 (https=) |
| CO (2) | CO2020002959A2 (https=) |
| CR (1) | CR20200123A (https=) |
| CY (1) | CY1124953T1 (https=) |
| DK (2) | DK3668513T3 (https=) |
| EC (1) | ECSP20018487A (https=) |
| ES (3) | ES2905100T3 (https=) |
| FI (1) | FI3668512T3 (https=) |
| HR (2) | HRP20220039T1 (https=) |
| HU (2) | HUE061910T2 (https=) |
| IL (3) | IL272599B (https=) |
| LT (2) | LT3668513T (https=) |
| MD (1) | MD3668513T2 (https=) |
| MX (2) | MX2020001833A (https=) |
| MY (1) | MY204421A (https=) |
| PE (1) | PE20200724A1 (https=) |
| PH (1) | PH12020500343B1 (https=) |
| PL (2) | PL3668513T3 (https=) |
| PT (2) | PT3668513T (https=) |
| RS (2) | RS62871B1 (https=) |
| SG (2) | SG11202001262QA (https=) |
| SI (2) | SI3668512T1 (https=) |
| SM (2) | SMT202200023T1 (https=) |
| TW (3) | TWI796353B (https=) |
| UA (1) | UA126292C2 (https=) |
| WO (3) | WO2019035864A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3483164T (lt) | 2017-03-20 | 2020-05-11 | Forma Therapeutics, Inc. | Pirolpirolo kompozicijos kaip piruvato kinazės (pkr) aktyvatoriai |
| TWI796353B (zh) * | 2017-08-15 | 2023-03-21 | 美商阿吉歐斯製藥公司 | 丙酮酸激酶調節劑及其用途 |
| EP3697354A4 (en) | 2017-10-20 | 2021-06-30 | The Regents of The University of Michigan | EYE DISEASE COMPOSITIONS AND METHODS |
| EP3852791B1 (en) | 2018-09-19 | 2024-07-03 | Novo Nordisk Health Care AG | Activating pyruvate kinase r |
| EP3853206B1 (en) | 2018-09-19 | 2024-04-10 | Novo Nordisk Health Care AG | Treating sickle cell disease with a pyruvate kinase r activating compound |
| BR112021015996A2 (pt) * | 2019-02-13 | 2021-11-09 | Agios Pharmaceuticals Inc | Derivados de tieno[3,2-b]pirrol[3,2-d]piridazinona e seu uso como derivados de pkm2 para o tratamento de câncer, obesidade e distúrbios relacionados a diabetes |
| WO2020262419A1 (ja) * | 2019-06-26 | 2020-12-30 | 日産化学株式会社 | 電荷輸送性ワニス |
| HRP20251148T1 (hr) | 2019-09-19 | 2025-11-21 | Novo Nordisk Health Care Ag | Pripravci koji aktiviraju piruvat-kinazu r (pkr) |
| EP4185293A4 (en) * | 2020-07-21 | 2025-01-15 | The Regents of The University of Michigan | COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE |
| CN112490502B (zh) * | 2020-12-04 | 2022-01-21 | 广州天赐高新材料股份有限公司 | 一种电解液及锂二次电池 |
| US11566030B2 (en) | 2021-02-08 | 2023-01-31 | Global Blood Therapeutics, Inc. | Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| WO2023052783A1 (en) * | 2021-09-30 | 2023-04-06 | Sitryx Therapeutics Limited | Novel compounds |
| IL312679A (en) * | 2021-11-16 | 2024-07-01 | Agios Pharmaceuticals Inc | Compounds for the treatment of anemia associated with MDS and other conditions |
| CN116159061A (zh) * | 2023-03-09 | 2023-05-26 | 上海市第十人民医院 | 丙酮酸激酶m2激活剂在制备预防或治疗心力衰竭的药物中的应用 |
| EP4671102A1 (en) | 2023-03-28 | 2025-12-31 | Honda Motor Co., Ltd. | METHOD FOR PROVIDING INFORMATION, PROGRAM FOR PROVIDING INFORMATION, STORAGE MEDIA AND INFORMATION PROCESSING APPARATUS |
| TW202509043A (zh) | 2023-05-15 | 2025-03-01 | 美商阿吉歐斯製藥公司 | ２－（（１ｈ－吡唑－３－基）甲基）－６－（（６－胺基吡啶－２－基）甲基）－４－甲基－４，６－二氫－５ｈ－噻唑基［５＇，４＇：４，５］吡咯并［２，３－ｄ］嗒𠯤－５－酮之結晶形式 |
| KR20260035223A (ko) * | 2023-07-05 | 2026-03-12 | 아지오스 파마슈티컬스 아이엔씨. | 피루브산 키나아제 활성화제의 합성 |
| TW202539675A (zh) | 2024-03-27 | 2025-10-16 | 美商阿吉歐斯製藥公司 | Ｐｋ活化劑在治療鐮狀細胞疾病中之用途 |
| WO2026076363A1 (en) | 2024-10-04 | 2026-04-09 | Agios Pharmaceuticals, Inc. | Compounds for treating mds-associated anemias and other conditions |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4405635A (en) | 1979-06-18 | 1983-09-20 | Merrell Dow Pharmaceuticals Inc. | 4-Aroylimidazol-2-ones and their use as pharmaceuticals |
| US4883914A (en) | 1987-08-17 | 1989-11-28 | American Cyanamid Company | Benzenesulfonyl carboxamide compounds useful as herbicidal agents |
| CA2380644A1 (en) | 1999-07-30 | 2001-02-08 | Basf Aktiengesellschaft | 2-pyrazolin-5-ones |
| CA2381581A1 (en) | 1999-09-04 | 2001-03-15 | Astrazeneca Ab | Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity |
| EP1972629A1 (en) * | 2007-03-23 | 2008-09-24 | Mutabilis SA | New imidazolo-heteroaryl derivatives with antibacterial properties |
| FR2933983B1 (fr) * | 2008-07-15 | 2010-08-27 | Servier Lab | Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| MX2011000843A (es) * | 2008-07-23 | 2011-04-11 | Vertex Pharma | Inhibidores de pirazolopiridin cinasa triciclicos. |
| EP2334673A1 (en) * | 2008-08-29 | 2011-06-22 | Amgen Inc. | PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF |
| WO2010042867A2 (en) | 2008-10-09 | 2010-04-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Activators of human pyruvate kinase |
| CA2758071C (en) * | 2009-04-06 | 2018-01-09 | Agios Pharmaceuticals, Inc. | Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use |
| TWI598337B (zh) | 2009-06-29 | 2017-09-11 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| US20130109672A1 (en) | 2010-04-29 | 2013-05-02 | The United States Of America,As Represented By The Secretary, Department Of Health And Human Service | Activators of human pyruvate kinase |
| KR101861883B1 (ko) | 2010-12-06 | 2018-05-28 | 글락소 그룹 리미티드 | Lp-PLA₂에 의해 매개되는 질환 또는 상태의 치료에 사용하기 위한 피리미디논 화합물 |
| TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| CN103608016A (zh) * | 2011-05-03 | 2014-02-26 | 安吉奥斯医药品有限公司 | 丙酮酸激酶激活剂在治疗中的用途 |
| US9388164B2 (en) * | 2011-05-03 | 2016-07-12 | Agios Pharmaceuticals, Inc | Methods of using pyruvate kinase activators |
| WO2012151450A1 (en) | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia |
| SMT202400081T1 (it) * | 2011-05-03 | 2024-03-13 | Agios Pharmaceuticals Inc | Attivatori della piruvato chinasi per uso in terapia |
| HK1198443A1 (en) * | 2011-07-19 | 2015-04-24 | 无限药品股份有限公司 | Heterocyclic compounds and uses thereof |
| WO2013056153A1 (en) * | 2011-10-13 | 2013-04-18 | Kung Charles | Activators of pyruvate kinase m2 and methods of treating disease |
| US9921221B2 (en) | 2012-07-26 | 2018-03-20 | Joslin Diabetes Center, Inc. | Predicting and treating diabetic complications |
| EA032007B1 (ru) | 2012-11-08 | 2019-03-29 | Аджиос Фармасьютикалз, Инк. | Терапевтические соединения и композиции и их использование в качестве модуляторов пк-m2 |
| WO2014118135A1 (en) * | 2013-01-30 | 2014-08-07 | Bayer Pharma Aktiengesellschaft | Amidoimidazopyridazines as mknk-1 kinase inhibitors |
| EP2968323A4 (en) | 2013-03-13 | 2016-12-14 | Flatley Discovery Lab | PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS |
| WO2014139144A1 (en) | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| AR097543A1 (es) * | 2013-09-06 | 2016-03-23 | Lexicon Pharmaceuticals Inc | COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO |
| US11465992B2 (en) | 2017-07-07 | 2022-10-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| MX2020001776A (es) | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| AR112475A1 (es) | 2017-08-15 | 2019-10-30 | Agios Pharmaceuticals Inc | Moduladores de piruvato quinasas y uso de los mismos |
| US10676485B2 (en) | 2017-08-15 | 2020-06-09 | Abbvie Inc. | Macrocyclic MCL-1 inhibitors and methods of use |
| TWI796353B (zh) | 2017-08-15 | 2023-03-21 | 美商阿吉歐斯製藥公司 | 丙酮酸激酶調節劑及其用途 |
| BR112021015996A2 (pt) * | 2019-02-13 | 2021-11-09 | Agios Pharmaceuticals Inc | Derivados de tieno[3,2-b]pirrol[3,2-d]piridazinona e seu uso como derivados de pkm2 para o tratamento de câncer, obesidade e distúrbios relacionados a diabetes |
-
2018
- 2018-08-15 TW TW107128431A patent/TWI796353B/zh active
- 2018-08-15 MX MX2020001833A patent/MX2020001833A/es unknown
- 2018-08-15 RS RS20220003A patent/RS62871B1/sr unknown
- 2018-08-15 PL PL18779068T patent/PL3668513T3/pl unknown
- 2018-08-15 RS RS20230354A patent/RS64221B1/sr unknown
- 2018-08-15 SM SM20220023T patent/SMT202200023T1/it unknown
- 2018-08-15 PE PE2020000245A patent/PE20200724A1/es unknown
- 2018-08-15 CN CN201880053315.9A patent/CN111032045B/zh active Active
- 2018-08-15 EP EP18766063.4A patent/EP3668881B1/en active Active
- 2018-08-15 EP EP18766400.8A patent/EP3668512B1/en active Active
- 2018-08-15 SM SM20230146T patent/SMT202300146T1/it unknown
- 2018-08-15 MY MYPI2020000757A patent/MY204421A/en unknown
- 2018-08-15 US US16/639,086 patent/US11464775B2/en active Active
- 2018-08-15 FI FIEP18766400.8T patent/FI3668512T3/fi active
- 2018-08-15 CA CA3072455A patent/CA3072455A1/en active Pending
- 2018-08-15 ES ES18779068T patent/ES2905100T3/es active Active
- 2018-08-15 US US16/639,075 patent/US11364240B2/en active Active
- 2018-08-15 SG SG11202001262QA patent/SG11202001262QA/en unknown
- 2018-08-15 PL PL18766400.8T patent/PL3668512T3/pl unknown
- 2018-08-15 PT PT187790688T patent/PT3668513T/pt unknown
- 2018-08-15 PT PT187664008T patent/PT3668512T/pt unknown
- 2018-08-15 AU AU2018316588A patent/AU2018316588B2/en active Active
- 2018-08-15 KR KR1020207007346A patent/KR102642408B1/ko active Active
- 2018-08-15 HU HUE18766400A patent/HUE061910T2/hu unknown
- 2018-08-15 AU AU2018316587A patent/AU2018316587B2/en active Active
- 2018-08-15 DK DK18779068.8T patent/DK3668513T3/da active
- 2018-08-15 SG SG11202001353PA patent/SG11202001353PA/en unknown
- 2018-08-15 EP EP21207073.4A patent/EP4026838A1/en not_active Withdrawn
- 2018-08-15 WO PCT/US2018/000128 patent/WO2019035864A1/en not_active Ceased
- 2018-08-15 CN CN202310962497.4A patent/CN117186119B/zh active Active
- 2018-08-15 CR CR20200123A patent/CR20200123A/es unknown
- 2018-08-15 BR BR112020003254-9A patent/BR112020003254A2/pt not_active Application Discontinuation
- 2018-08-15 SI SI201830914T patent/SI3668512T1/sl unknown
- 2018-08-15 CN CN201880053325.2A patent/CN111032046B/zh active Active
- 2018-08-15 WO PCT/US2018/000127 patent/WO2019035863A1/en not_active Ceased
- 2018-08-15 TW TW107128429A patent/TWI790271B/zh active
- 2018-08-15 PH PH1/2020/500343A patent/PH12020500343B1/en unknown
- 2018-08-15 KR KR1020207007344A patent/KR102717594B1/ko active Active
- 2018-08-15 LT LTEPPCT/US2018/000128T patent/LT3668513T/lt unknown
- 2018-08-15 JP JP2020508455A patent/JP7301040B2/ja active Active
- 2018-08-15 HR HRP20220039TT patent/HRP20220039T1/hr unknown
- 2018-08-15 IL IL272599A patent/IL272599B/en unknown
- 2018-08-15 UA UAA202001747A patent/UA126292C2/uk unknown
- 2018-08-15 US US16/639,081 patent/US11590132B2/en active Active
- 2018-08-15 DK DK18766400.8T patent/DK3668512T3/da active
- 2018-08-15 LT LTEPPCT/US2018/000129T patent/LT3668512T/lt unknown
- 2018-08-15 JP JP2020508498A patent/JP7275107B2/ja active Active
- 2018-08-15 ES ES18766063T patent/ES2966825T3/es active Active
- 2018-08-15 EP EP18779068.8A patent/EP3668513B1/en active Active
- 2018-08-15 WO PCT/US2018/000129 patent/WO2019035865A1/en not_active Ceased
- 2018-08-15 HR HRP20230452TT patent/HRP20230452T1/hr unknown
- 2018-08-15 MX MX2020001832A patent/MX2020001832A/es unknown
- 2018-08-15 MD MDE20200663T patent/MD3668513T2/ro unknown
- 2018-08-15 SI SI201830558T patent/SI3668513T1/sl unknown
- 2018-08-15 ES ES18766400T patent/ES2944545T3/es active Active
- 2018-08-15 HU HUE18779068A patent/HUE057178T2/hu unknown
- 2018-08-15 TW TW111135803A patent/TWI823580B/zh active
- 2018-08-15 KR KR1020237028222A patent/KR102764124B1/ko active Active
-
2020
- 2020-02-11 IL IL272597A patent/IL272597B/en unknown
- 2020-02-13 CL CL2020000375A patent/CL2020000375A1/es unknown
- 2020-03-12 CO CONC2020/0002959A patent/CO2020002959A2/es unknown
- 2020-03-12 CO CONC2020/0002961A patent/CO2020002961A2/es unknown
- 2020-03-13 EC ECSENADI202018487A patent/ECSP20018487A/es unknown
- 2020-11-19 US US16/952,257 patent/US11040036B2/en active Active
-
2022
- 2022-01-18 CY CY20221100039T patent/CY1124953T1/el unknown
- 2022-01-27 US US17/586,777 patent/US11872225B2/en active Active
- 2022-04-26 IL IL292530A patent/IL292530B2/en unknown
- 2022-05-16 US US17/744,806 patent/US11957680B2/en active Active
- 2022-12-14 JP JP2022199462A patent/JP2023027276A/ja active Pending
-
2023
- 2023-01-18 JP JP2023005925A patent/JP7530453B2/ja active Active
- 2023-01-20 US US18/099,311 patent/US12133853B2/en active Active
- 2023-05-03 AU AU2023202772A patent/AU2023202772B2/en active Active
-
2024
- 2024-07-26 JP JP2024121066A patent/JP2024147805A/ja active Pending
- 2024-08-16 AU AU2024205818A patent/AU2024205818A1/en not_active Abandoned
- 2024-09-12 US US18/882,884 patent/US20250144093A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020531443A5 (https=) | ||
| HRP20220039T1 (hr) | Aktivatori piruvat kinaze za uporabu u liječenju krvnih poremećaja | |
| JP2015143283A5 (https=) | ||
| JP2022516469A5 (https=) | ||
| JP2021504338A5 (https=) | ||
| JP2016512203A5 (https=) | ||
| HRP20180863T1 (hr) | Aktivatori piruvat kinaze za uporabu u terapiji | |
| JP2017526675A5 (https=) | ||
| JP2022501354A5 (https=) | ||
| CA3080959A1 (en) | Modulators of the integrated stress pathway | |
| JP2017019839A5 (https=) | ||
| JP2001526269A5 (https=) | ||
| JP2012532136A5 (https=) | ||
| RU2014129742A (ru) | Производные бензолсульфонамида в качестве модуляторов rorc | |
| CA3080808A1 (en) | Modulators of the integrated stress pathway | |
| RU2015101102A (ru) | Гетероароматическое метильное производное циклического амина | |
| NZ604074A (en) | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer | |
| CA3080964A1 (en) | Modulators of the integrated stress pathway | |
| JP2018502906A5 (https=) | ||
| JP2014524934A5 (https=) | ||
| JP2017510610A5 (https=) | ||
| RU2009133259A (ru) | Производные пиразола в качестве ингибиторов 11-бета-hsd1 | |
| JP2015501833A5 (https=) | ||
| JP2009526830A5 (https=) | ||
| JP2022514385A5 (https=) |